Re-uptake blockers are a class of antidepressants proposed to achieve their clinical effects in people by inhibiting presynaptic norepinephrine and/or serotonin re-uptake transporters, which normally function to terminate transmitter signaling at synapses. It has never adequately been explained, however, why therapeutic relief of depression takes weeks when this particular action of re-uptake blockers occurs within hours of drug administration. 1 A requirement for some form of adaptation at synapses is a frequently cited possibility, but recent work has also highlighted that there are a myriad of non-classical targets for re-uptake blockers, such as EAG-like K + -channels (blocked by imipramine) 2 and novel membrane-spanning proteins typified by NRF-6 and NDG-4, identified as fluoxetine targets in a recent screen in worms 3 . With the recent discovery of mutants in
mod-5 , a gene encoding the C. elegans serotonin re-uptake transporter, 4 a new approach to tackling this long-standing question has emerged. Utilizing the DNA microarray facility at Stuart Kim's laboratory in Stanford, we have begun work on a gene chip project to perform a four-way comparison between N2 and
mod-5(
n3314) worms (
n3314 is a 1.6 kb deletion in the
mod-5 genomic locus), each on and off fluoxetine. We hope to understand what baseline transcriptional differences exist between the two genotypes, how similar the effects of chronic fluoxetine in N2 are to the effects of a complete absence of MOD-5 in
mod-5(
n3314) worms, and to identify which gene expression changes induced by fluoxetine are MOD-5-dependent and which are MOD-5-independent. A preliminary experiment is expected to be completed by the end of April, 2001. 1 Schafer WR, Cell 98 :551-554 2 Weinshenker D et al . J Neurosci 19 :9831-9840 3 Choy RK et al . Mol Cell 4 :143-152 4 Ranganathan R and Horvitz HR, 1999 International Worm Meeting, abstract 70